Bovine Insulin: From Lifesaving Discovery to Recombinant Replacement

Bovine insulin, extracted from cattle pancreases, was the first clinically used insulin (1922) and dominated diabetes therapy for 60 years.

Why Bovine Insulin Was the First Choice

  • Supply: Cattle pancreases were abundant byproducts of the meat industry; scalable
  • Extraction: Established acid-ethanol process (Banting/Best/Collip)
  • Structural similarity: Differs from human insulin by only 3 amino acids (A8 Thr→Ala, A10 Ile→Val, B30 Thr→Ala)
  • Immunogenicity: Lower than porcine insulin (1 AA difference); most patients tolerated it after initial antibody formation

Limitations That Drove Change

  • Anti-insulin antibodies → insulin resistance, local reactions, lipodystrophy
  • Batch variability; purity improved but never reached perfection
  • Ethical/religious concerns for some patients

Transition to Human Insulin

  • 1970s: Chemical modification (enzymatic conversion of porcine → semi-synthetic human insulin)
  • 1982: Recombinant human insulin (Humulin, Novolin)—first FDA-approved rDNA drug
  • Advantages: identical to human insulin, consistent quality, scalable, lower immunogenicity, no animal pathogen risk
  • By 1990s: >95% market share in developed countries

Current Status

  • Bovine insulin discontinued in US (1998), UK, Canada; still available in some countries
  • Porcine insulin also largely replaced
  • Modern analogs (lispro, aspart, glargine, degludec) offer pharmacokinetic advantages over regular human insulin

Historical significance: Bovine insulin saved millions of lives; its replacement by recombinant technology revolutionized biopharmaceutical manufacturing.

Diabetes - Related Articles